Edward J. Dulac III, Chief Financial Officer at FATE THERAPEUTICS INC (FATE), sold 5,182 shares at $3.66 ($19K) on 2024-01-02, disclosed to the SEC on 2024-01-03.
Scheduled sale ($19k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NTLA | SELL | 2026-01-07 | $59K | — | Filing → |
| NTLA | SELL | 2025-07-25 | $209K | — | Filing → |
| FATE | SELL | 2024-03-05 | $19K | — | Filing → |